An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Inclusion Criteria:

- Treatment-compliant patients who are participating in qualifying ongoing studies and
have completed required End-of-Treatment and/or Follow-up visits in a prior clinical
study with bardoxolone methyl and who, according to the assessment of the
investigator, have a potential positive benefit-risk assessment for participating in
the trial.

- Meets the following eligibility criteria from the prior qualifying study. Patients not
meeting the following criteria may be eligible and must be discussed with the medical
monitor prior to enrollment to assess their current clinical status:

1. eGFR ≥ 30 mL/min/1.73 m2 at the last on-treatment visit in the prior qualifying
study;

2. BNP < 200 pg/mL at the last on-treatment visit in the prior qualifying study;

3. No occurrence of a cardiovascular serious adverse event in the prior qualifying
study.

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
and other study procedures.

Exclusion Criteria:

- Participation in other investigational clinical studies involving interventional
products being tested or used in a way different from the approved form or when used
for an unapproved indication;

- Patients who have an ongoing SAE from a clinical study that is assessed by the
investigator as related to bardoxolone methyl;

- Unwilling to practice acceptable methods of birth control (both males who have
partners of childbearing potential and females of childbearing potential) while taking
study drug;

- Women who are pregnant or breastfeeding;

- Patient is, in the opinion of the investigator, unable to comply with the requirements
of the study protocol or is unsuitable for the study for any reason;

- Known hypersensitivity to any component of the study drug.